Search | Clinical Trials Finder

Conditions: Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions: Autologous cultured dermal and epidermal cells; Biological
Lead sponsor: Aderans Research Institute; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2010
U.S. locations: 2
States / cities: Los Angeles, California • New Hyde Park, New York

Conditions: Diabetic Kidney Disease
Interventions: rhubarb extract, placebo; Dietary Supplement
Lead sponsor: Wake Forest University; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Alport Syndrome
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 1 Year and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Autosomal Dominant Polycystic Kidney Disease
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 40 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Urinary Incontinence
Interventions: Pelvic Floor Muscle exercises; Procedure
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older · Female only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Bladder Cancer
Interventions: Pembrolizumab, Entinostat, Procedure/Surgery; Drug · Procedure
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Philadelphia, Pennsylvania

Conditions: Bladder Cancer
Interventions: Mycobacterial Cell-Wall DNA Complex, Bacillus Calmette-Guerin; Biological
Lead sponsor: Bioniche Life Sciences Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 14
States / cities: Laguna Hills, California • Los Angeles, California • San Diego, California + 11 more

Conditions: Relapsed/Refractory Solid Tumors/Hematological Malignancies
Interventions: Belinostat; Drug
Lead sponsor: Acrotech Biopharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Whittier, California • Canton, Ohio

Conditions: Bladder Cancer, Urothelial Carcinoma
Interventions: 18F-fluciclovine, PET/CT; Drug · Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Renal Impairment, Hemodialysis
Interventions: INCB000928; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 82 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: Rialto, California • Hialeah, Florida • Miami, Florida + 2 more

Conditions: Cardiomyopathy, Renal Impairment
Interventions: Tadalafil, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years to 90 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Prostate Neoplasms
Interventions: PS-341 (bortezomib); Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: Conventional 3D-CRT or IMRT, Hypofractionated 3D-CRT or IMRT; Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 1,116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2022
U.S. locations: 282
States / cities: Phoenix, Arizona • Tucson, Arizona • Auburn, California + 200 more

Conditions: Adenocarcinoma, Prostate Cancer, Neoplasms, Carcinoma, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type
Interventions: TriAdeno vaccine, N-803; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: End Stage Renal Disease, Thrombosis
Interventions: AB023- Dose 1, AB023-Dose 2, placebo; Drug
Lead sponsor: Aronora, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Prostate Neoplasms
Interventions: Abiraterone acetate, Glucocorticoid; Drug
Lead sponsor: Cougar Biotechnology, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 2
States / cities: San Francisco, California • New York, New York

Conditions: Solid Tumors
Interventions: Trabectedin (ecteinascidin-743, ET-743, YONDELIS [R]); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 4 Years to 16 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Kidney Disease, Cardiovascular Disease
Interventions: Fish Oil and Bicarbonate, Fish Oil and Bicarbonate Placebo, Fish Oil Placebo and Bicarbonate, Fish Oil Placebo and Bicarbonate Placebo; Dietary Supplement
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 60 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Systemic Lupus Erythematosus, Lupus Nephritis
Interventions: IMPT-514; Biological
Lead sponsor: Lyell Immunopharma, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Los Angeles, California • San Francisco, California • Iowa City, Iowa

Conditions: Obsessive-Compulsive Disorder
Interventions: olanzapine + fluoxetine, placebo + fluoxetine; Drug
Lead sponsor: University of Florida; Other
Eligibility: 14 Years to 70 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2003
U.S. locations: 2
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: Chronic Kidney Disease, Proteinuria, Children
Interventions: Finerenone (Kerendia, BAY94-8862); Drug
Lead sponsor: Bayer; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 18
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 15 more

Conditions: Breast Cancer, Prostate Cancer, Colorectal Cancer
Interventions: PN+LCNC, PN Only; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2017
U.S. locations: 2
States / cities: Chicago, Illinois • San Antonio, Texas

Conditions: Bladder Cancer
Interventions: Ascorbic Acid; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 3
States / cities: Fairway, Kansas • Kansas City, Kansas

Conditions: Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8
Interventions: Therapeutic Conventional Surgery, Avelumab, Gemcitabine Hydrochloride, Carboplatin; Procedure · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 92
States / cities: Aurora, Colorado • Highlands Ranch, Colorado • Orlando, Florida + 70 more

Search by objective public record fields.

A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542)

Rhubarb and Angiotensin Converting Enzyme Inhibitor

Multi-center Controlled Clinical Trials in Alport Syndrome-A Feasibility Study

Assessment of Longitudinal Changes in Endothelial Function and Oxidative Stress in Normotensive Patients With ADPKD

Low-Intensity Physical Therapy for Prevention of Pre and Postpartum Urinary Incontinence

Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer

First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC

To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.

18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis

Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Diastolic Cardiomyopathy (Aim3)

PS-341 Followed by Removal of Prostate for Those With Prostate Cancer

Radiation Therapy in Treating Patients With Stage II Prostate Cancer

Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis

An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

Tabectedin to Treat Children and Adolescents With Cancer

Pathways to Improving Functional Capacity in Older Patients With Chronic Kidney Disease and Cardiovascular Disease

A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

Treatment of Obsessive-Compulsive Disorder

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

Redes III Patient Navigator Qol Study

Intravenous (IV) Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients

Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)